



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

14.08.2024

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Ref: Regulation 30 of the SEBI (Listing Obligations and Di'sclosure Requirements) Regulations, 2015 ('listing Regulations')

Sub: Outcome of the Board Meeting.

Pursuant to Regulation 30 read with Part A of Schedule III, of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held on 14th August 2024, had, inter-alia transacted the following items of the business:

1. Approved the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2024.
2. Took note of the Limited Review Report on Financial results of the Company for the quarter ended on 30th June 2024 as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

The Board Meeting Commenced at 03:00 P.M and concluded at 04:20 PM

A Copy of said results together with the limited review report is enclosed herewith for the First quarter ended 30th June 2024 are enclosed herewith.

These are also made available on the website of the company at www.godavaridrugs.com

This is for your information and records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer
Membership Number : A53326



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

14.08.2024

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Submission of Un-Audited Standalone and Consolidated Financial Results of the Company, for the quarter ended on 30th June 2024 as per the provisions of SEBI (IODR) Regulations, 2015

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-Audited Standalone Financial Results of the Company for the first quarter ended 30th June 2024.
2. Limited Review Report on Standalone Financial results of the Company for the first quarter ended on 30th June, 2024 as required under Regulation 33 of SEBI (LODR) Regulations, 2015

These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting Commenced at 03.00 P.M and concluded at 04:20 PM

Please take the above in your records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer

GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Sl. No.	Particulars	Standalone			
		Quarter ended		Year ended	
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	3220.75	3864.01	3541.88	15671.19
2	Other Income	76.51	11.17	45.21	61.75
3	Total Revenue from operations (1+2)	3297.26	3875.18	3587.09	15732.94
4	Expenses				
	(a) Cost of materials consumed	2694.83	3220.44	2644.34	12194.76
	(b) Changes in inventories of finished goods & work-in-progress	-354.06	-454.29	162.33	-113.67
	(c) Employee benefits expense	126.43	144.74	121.95	513.05
	(d) Depreciation & amortization expenses	54.96	53.16	47.38	199.46
	(e) Finance Costs	143.52	123.23	110.98	491.50
	(f) Other Expenses	430.37	505.78	388.39	1746.62
	Total expenses	3096.05	3593.06	3475.37	15031.72
5	Profit before exceptional Items and tax (3-4)	201.21	282.12	111.72	701.22
6	Exceptional items	-	-3.21	-	-9.04
7	Profit before Tax (5+6)	201.21	278.91	111.72	692.18
8	Tax expense	-38.13	-12.72	-30.68	-137.28
9	Net Profit for the period (7-8)	163.08	266.19	81.04	554.90
10	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-
11	Total Comprehensive Income (9+10)	163.08	266.19	81.04	554.90
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05
13	Other Equity		3143.56		3143.56
14	Earnings per share				
	(a) Basic	2.17	3.53	1.08	7.37
	(b) Diluted	2.17	3.53	1.08	7.37

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th August, 2024.
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED



(Handwritten Signature)

Mohit Jaju

Wholetime Director & CFO

DIN: 03405414

Place: Secunderabad

Date : 14.08.2024

Independent Auditor's Review Report on unaudited quarterly financial results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015


To,
The Board of Directors,
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter ended 30th June 2024 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 002785


Ayyadevara Srinivas
Proprietor
Membership No.028803
Secunderabad, Date :14/08/2024.
UDIN: 24028803BKHJGS1914

